These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9325467)

  • 1. Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications.
    Solerte SB; Fioravanti M; Cerutti N; Severgnini S; Locatelli M; Pezza N; Rondanelli M; Trecate L; Balza G; Ferrari E
    Acta Diabetol; 1997 Aug; 34(2):67-74. PubMed ID: 9325467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
    Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
    Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients.
    Ferrari E; Fioravanti M; Patti AL; Viola C; Solerte SB
    Pharmatherapeutica; 1987; 5(1):26-39. PubMed ID: 3602021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in patients with cerebrovascular insufficiency.
    Ott E; Lechner H; Fazekas F
    Eur Neurol; 1983; 22 Suppl 1():105-7. PubMed ID: 6884401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study.
    Solerte SB; Fioravanti M; Bozzetti A; Schifino N; Patti AL; Fedele P; Viola C; Ferrari E
    Acta Diabetol Lat; 1986; 23(2):171-7. PubMed ID: 3751450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline.
    Solerte SB; Ferrari E
    Pharmatherapeutica; 1985; 4(6):341-50. PubMed ID: 4080752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hemorheologic therapy applications in coronary heart disease].
    Leschke M; Motz W; Strauer BE
    Wien Med Wochenschr; 1986; 136 Spec No():17-24. PubMed ID: 3825169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes.
    Rodríguez-Morán M; Guerrero-Romero F
    Curr Diabetes Rev; 2008 Feb; 4(1):55-62. PubMed ID: 18220696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired hemorheological properties in diabetic patients with lower limb arterial ischaemia.
    Le Devehat C; Khodabandehlou T; Vimeux M
    Clin Hemorheol Microcirc; 2001; 25(2):43-8. PubMed ID: 11790869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy.
    Solerte SB; Fioravanti M; Patti AL; Schifino N; Zanoletti MG; Inglese V; Ferrari E
    Acta Diabetol Lat; 1987; 24(3):229-39. PubMed ID: 3687315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemorheology and peripheral vascular diseases: a new therapeutic approach.
    Müller R
    J Med; 1981; 12(4):209-35. PubMed ID: 7031157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pentoxifylline on hemodynamic, hemorheological, and microcirculatory parameters in young SHRs during arterial hypertension development.
    Plotnikov MB; Aliev OI; Shamanaev AY; Sidekhmenova AV; Anfinogenova Y; Anishchenko AM; Fomina TI; Arkhipov AM
    Clin Exp Hypertens; 2017; 39(6):570-578. PubMed ID: 28722518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of hemorheologically active treatment with pentoxifylline in patients with cerebrovascular disease.
    Schneider R
    Angiology; 1989 Nov; 40(11):987-93. PubMed ID: 2817522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease.
    Perego MA; Sergio G; Artale F; Giunti P; Danese C
    Curr Med Res Opin; 1986; 10(2):135-8. PubMed ID: 3709212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of various hemorheologic parameters in diabetes mellitus].
    Cella A; Bianchi E; Reali GL; Piana A; Armani U
    Boll Soc Ital Biol Sper; 1990 Apr; 66(4):335-42. PubMed ID: 2390223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trental treatment of microcirculatory disorders in diabetes mellitus and arteriosclerosis].
    Vogralik VG; Vogralik MV; Runov GP; Runova AA; Kostrov AI
    Klin Med (Mosk); 1982 Oct; 60(10):90-4. PubMed ID: 7176484
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hemorheologic findings in diabetes and their clinical relevance].
    Volger E
    Wien Med Wochenschr; 1986; 136 Spec No():5-10. PubMed ID: 3825172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pentoxifylline in the blood rheological and coagulative changes in chronic respiratory failure].
    Micillo E; Dericoloso A; Tranchese D; Bianco A; Sorrentino L; Di Filippo O
    Arch Monaldi Mal Torace; 1990; 45(1):31-8. PubMed ID: 1669259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modification of hemorheological parameters in microvascular complications of diabetes].
    Bauduceau B; Renaudeau C; Mayaudon H; Hélie C; Ducorps M; Sonnet E; Yvert JP
    Diabete Metab; 1995 Jun; 21(3):188-93. PubMed ID: 7556810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemorheologic conditions in patients with cerebrovascular disease altered by treatment with pentoxifylline.
    Ott E; Lechner H
    Ric Clin Lab; 1981; 11 Suppl 1():253-6. PubMed ID: 7188113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.